Roche Advocates for Sustainability in the Healthcare Industry

For the eighth year in a row, the Dow Jones Sustainability Index has ranked Roche the most sustainable healthcare company.

Roche is the world’s largest biotech company, and is focused on treating diseases such as cancer. The index analyzes economic, social, and environmental performance for leading healthcare companies to provide additional information for investors.

Approximately 3450 publically traded companies are invited to participate in the assessment, but only industry leaders are included in the index. Each company submits a questionnaire supplemented with documentation, media coverage, stakeholder comments, and other publicly available sources, according to Roche.

This year’s index identified Roche as a group leader in sustainability within the pharmaceuticals, biotechnology, and life sciences industry. Through the analysis, Dow Jones found that Roche performed well in many of the categories, and they maintained leadership in the healthcare industry through its sustainability strategy seen throughout aspects of the company.

The focus of this year’s review was on access, compliance, transparency, diverse work culture, and collaborating with diverse partners, according to Roche. Roche said they recently took steps to respond to the 17 Sustainable Development Goals, which aims to end poverty, conserve the environment, and promote worldwide success.

They have integrated the Development Goals into their business strategy especially the goal that promotes healthy lives and well-being, Roche said.

“We are very proud of this recognition,” says Roche CEO Severin Schwan. “Our selection once again as the world’s most sustainable healthcare company was only possible through the dedicated efforts of Roche employees across the Group. Sustainability is an integral part of what we do at Roche and at the heart of our business, now and in the future. I strongly believe that our main contribution to society is improving healthcare, developing diagnostic tests and medicines to meet some of the most urgent medical needs. If we are successful in exactly doing this, we will have a long and lasting impact.”